Valuation: GlaxoSmithKline Pharmaceuticals Limited

Market Cap 432B 4.49B 3.93B 3.64B 3.35B 6.33B 6.4B 43.5B 17.02B 212B 16.84B 16.48B 731B P/E 2027 *
37.6x
P/E 2028 * 33.4x
Enterprise Value 432B 4.49B 3.93B 3.64B 3.35B 6.33B 6.4B 43.5B 17.02B 212B 16.84B 16.48B 731B EV / Sales 2027 *
10.3x
EV / Sales 2028 * 9.3x
Free-Float
24.37%
Yield 2027 *
1.16%
Yield 2028 * 1.16%

Last Transcript: GlaxoSmithKline Pharmaceuticals Limited

1 day+1.83%
1 week+3.55%
Current month+4.09%
1 month+9.36%
3 months+5.12%
6 months+12.18%
Current year+3.24%
1 week 2,431
Extreme 2431
2,562
1 month 2,334.35
Extreme 2334.35
2,562
Current year 2,088
Extreme 2088
2,715.15
1 year 2,088
Extreme 2088
3,217.1
3 years 1,381.6
Extreme 1381.6
3,515.95
5 years 1,228
Extreme 1228
3,515.95
10 years 1,020
Extreme 1020
3,515.95
Manager TitleAgeSince
Chief Executive Officer 56 2022-11-30
Director of Finance/CFO - 2026-03-31
Chief Tech/Sci/R&D Officer - 2024-07-07
Director TitleAgeSince
Director/Board Member 64 2017-04-06
Chairman 73 2019-03-31
Director/Board Member 59 2020-05-17
Change 5-day change 1-year change 3-year change Capi.($)
+1.83%+3.55%-18.16%+82.46% 4.41B
-0.61%+0.63%+49.91%+153.41% 1,048B
+1.90%+3.33%+51.99%+49.19% 603B
+0.19%+5.03%+37.03%+79.07% 452B
-0.09%+1.00%+31.25%+21.94% 327B
-0.37%+2.52%+35.74%+37.75% 283B
+1.71%+1.13%+22.76%+17.88% 259B
-1.40%-3.34%-24.63%-41.91% 219B
+0.61%+2.59%+20.25%+56.14% 198B
+0.93%-0.24%+19.26%+69.19% 162B
Average +0.47%+1.73%+22.54%+52.51% 355.61B
Weighted average by Cap. +0.25%+1.69%+36.09%+73.74%

Financials

2027 *2028 *
Net sales 41.99B 436M 382M 354M 326M 615M 622M 4.23B 1.65B 20.58B 1.64B 1.6B 71.05B 46.49B 483M 423M 392M 361M 680M 689M 4.68B 1.83B 22.78B 1.81B 1.77B 78.67B
Net income 11.42B 119M 104M 96.28M 88.62M 167M 169M 1.15B 450M 5.6B 445M 435M 19.32B 12.54B 130M 114M 106M 97.35M 184M 186M 1.26B 494M 6.15B 489M 478M 21.22B
Net Debt - -
Logo GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.
Employees
3,103
Date Price Change Volume
26-07-22 2,551.10 +1.83% 4,731
26-07-21 ₹2,505.30 +0.79% 3,412
26-07-20 ₹2,485.65 +1.25% 5,238
26-07-17 ₹2,455.05 -2.06% 3,304
26-07-16 ₹2,506.70 +0.85% 3,034
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2,505.30INR
Average target price
2,969.75INR
Spread / Average Target
+18.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLAXO Stock